GoldHaven Resources Reports Bonanza Grade Assays from Magno Project
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 07 2026
0mins
Source: Globenewswire
- Strategic Material Discovery: GoldHaven Resources Corp. reported silver grades as high as 2,370 g/t, tungsten at 6,550 ppm, and indium at 334 ppm from its Magno Project, highlighting the asset's strategic importance as a potential source of critical minerals.
- Positive Market Reaction: The market is treating this data as a precious metals story, reflecting strong demand for strategic material inventories, with a stark valuation disconnect between GoldHaven's current trading and its potential production capabilities.
- Enhanced Policy Support: Recent accelerated permitting reforms in British Columbia, committing to a 'one project, one review' system, further promote critical minerals development, placing GoldHaven in a favorable regulatory environment.
- Significant Geological Context: The Magno Property is located in the historically productive Cassiar District with existing infrastructure, and confirmation drilling is delivering grades above economic thresholds, enhancing its potential as a near-term production candidate.
Analyst Views on ONCY
Wall Street analysts forecast ONCY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ONCY is 5.50 USD with a low forecast of 3.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.973
Low
3.00
Averages
5.50
High
10.00
Current: 0.973
Low
3.00
Averages
5.50
High
10.00
About ONCY
Oncolytics Biotech Inc. is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype, turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. The Company is also advancing its programs in hormone receptor-positive / human epidermal growth factor 2-negative (HR+/ HER2-) advanced and metastatic breast cancer (mBC) and metastatic pancreatic ductal adenocarcinoma (PDAC) to registration-enabled clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
